Svb Leerink cut shares of Diplomat Pharmacy (NYSE:DPLO) from an outperform rating to a market perform rating in a research report sent to investors on Monday. The brokerage currently has $6.00 price target on the stock, down from their prior price target of $24.00.
DPLO has been the subject of several other reports. William Blair lowered Diplomat Pharmacy from an outperform rating to a market perform rating in a report on Monday, January 7th. ValuEngine lowered Diplomat Pharmacy from a sell rating to a strong sell rating in a report on Monday, February 4th. Robert W. Baird raised Diplomat Pharmacy from an underperform rating to a neutral rating and upped their target price for the company from $10.00 to $15.00 in a report on Friday, December 7th. Zacks Investment Research lowered Diplomat Pharmacy from a hold rating to a strong sell rating in a report on Tuesday, November 27th. Finally, JPMorgan Chase & Co. lowered Diplomat Pharmacy from an overweight rating to a neutral rating and reduced their target price for the company from $9.00 to $8.00 in a report on Friday, February 22nd. Three investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and two have given a buy rating to the company. The stock presently has a consensus rating of Hold and a consensus price target of $13.78.
Get Diplomat Pharmacy alerts:DPLO stock opened at $6.31 on Monday. The company has a market capitalization of $446.82 million, a PE ratio of 7.51 and a beta of 0.98. The company has a debt-to-equity ratio of 0.58, a current ratio of 0.95 and a quick ratio of 0.66. Diplomat Pharmacy has a 12-month low of $5.56 and a 12-month high of $28.74.
A number of hedge funds and other institutional investors have recently made changes to their positions in DPLO. BDO Wealth Advisors LLC bought a new position in Diplomat Pharmacy during the fourth quarter valued at $27,000. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in Diplomat Pharmacy by 43.4% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,425 shares of the company’s stock valued at $46,000 after purchasing an additional 1,037 shares during the period. Oppenheimer Asset Management Inc. bought a new position in Diplomat Pharmacy during the fourth quarter valued at $69,000. Public Employees Retirement Association of Colorado grew its holdings in Diplomat Pharmacy by 142.2% during the third quarter. Public Employees Retirement Association of Colorado now owns 6,307 shares of the company’s stock valued at $122,000 after purchasing an additional 3,703 shares during the period. Finally, Xact Kapitalforvaltning AB bought a new position in Diplomat Pharmacy during the fourth quarter valued at $155,000. 84.49% of the stock is owned by institutional investors and hedge funds.
Diplomat Pharmacy Company Profile
Diplomat Pharmacy, Inc operates as an independent specialty pharmacy in the United States. The company stocks, dispenses, and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. It also provides specialty infusion pharmacy, patient care coordination, clinical, compliance and persistency program, patient financial assistance, specialty pharmacy training/consulting, benefits investigation, prior authorization, risk evaluation and medication strategy, retail specialty, and hub services, as well as clinical and administrative support services to hospitals and health systems.
Recommended Story: Why is cost of goods sold important?
No comments:
Post a Comment